Bayer Aktiengesellschaft (FRA:BAYN)
Germany
· Delayed Price · Currency is EUR 24.74
+0.01 (0.04%)
At close: May 30, 2025, 10:00 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| Crop Science | 21.93B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Crop Science Growth | -3.92% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceuticals | 18.32B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceuticals Growth | 1.60% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consumer Health | 5.94B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consumer Health Growth | 0.87% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Enabling Functions and Consolidation | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Enabling Functions and Consolidation Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| All Other Segment | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| All Other Segment Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBITDA by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| Crop Science Adjusted EBITDA | 4.03B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Crop Science Adjusted EBITDA Growth | -12.71% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceuticals Adjusted EBITDA | 4.87B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceuticals Adjusted EBITDA Growth | -7.71% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consumer Health Adjusted EBITDA | 1.38B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consumer Health Adjusted EBITDA Growth | 1.03% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Enabling Functions and Consolidation Adjusted EBITDA | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Enabling Functions and Consolidation Adjusted EBITDA Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| All Other Segment Adjusted EBITDA | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| All Other Segment Adjusted EBITDA Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| Europe/Middle East/Africa | 13.89B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe/Middle East/Africa Growth | -0.32% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America | 16.54B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America Growth | 2.68% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia/Pacific | 8.24B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia/Pacific Growth | 1.65% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Latin America | 7.91B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Latin America Growth | -10.76% |
Log In |
Log In |
Log In |
Log In | Upgrade
|